We observed that, in consecutive tumor samples collected from acromegaly patients, the inhibitory activity of OCT, PAS and OCT+PAS was superimposable (all drugs tested at 10−8 M concentration, for 72 h). The gene discussed is PLXNA2; the disease is acromegaly.